- •The optimal length of stay for acute heart failure (HF) hospitalization is uncertain.
- •Up to now, longer but also shorter stays are associated with an increased risk of HF readmission.
- •CA125 is a valuable biomarker for congestion, worse prognosis, and a valuable tool for guiding treatment in patients with HF.
- •Patients with CA125≥35 U/mL displayed higher rates of 6-month HF readmission.
- •LOS7 days shows a protective role in the risk of mid-term HF readmission in patients with high CA125 levels.
Abbreviations:AHF (acute heart failure), CA125 (antigen carbohydrate 125), CI (confidence interval), CRT (cardiac resynchronization therapy), ECG (electrocardiogram), HF (heart failure), HR (hazard ratios), ICD (implantable cardioverter-defibrillator), IQR (interquartile range), LOS (length of stay), LVEF (left ventricular ejection fraction), MUC16 (mucin 16), NT-proBNP (amino-terminal pro-brain natriuretic peptide), NYHA (New York Heart Association), SBP (systolic blood pressure)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Internal Medicine
- Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days.Am Heart J. 2013; 165: 987-994https://doi.org/10.1016/j.ahj.2013.02.006
- Relation of acute heart failure hospital length of stay to subsequent readmission and all-cause mortality.Am J Cardiol. 2015; 116: 400-405https://doi.org/10.1016/j.amjcard.2015.04.052
- Predictors and associations with outcomes of length of hospital stay in patients with acute heart failure: results from VERITAS.J Card Fail. 2016; 22: 815-822https://doi.org/10.1016/j.cardfail.2015.12.017
- Updates in heart failure 30-day readmission prevention.Heart Fail Rev. 2019; 24: 177-187https://doi.org/10.1016/j.cardfail.2015.12.017
- length of hospital stay and its impact on subsequent early readmission in patients with acute heart failure: a report from the WET-HF Registry.Heart Vessels. 2019; 34: 1777-1788https://doi.org/10.1007/s00380-019-01432-y
- length of stay and risk of very early readmission in acute heart failure.Eur J Intern Med. 2017; 42: 61-66https://doi.org/10.1016/j.ejim.2017.04.003
- Timing and causes of readmission after acute heart failure hospitalization—insights from the heart failure network trials.J Card Fail. 2016; 22: 875-883https://doi.org/10.1016/j.cardfail.2016.04.014
- Associations between short or long length of stay and 30-day readmission and mortality in hospitalized patients with heart failure.JACC Heart Fail. 2017; 5: 578-588https://doi.org/10.1016/j.jchf.2017.03.012
- Clinical role of CA125 in worsening heart failure.JACC Heart Fail. 2020; 8: 386-397https://doi.org/10.1016/j.jchf.2019.12.005
- improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure.Eur Heart J. 2010; 31: 1752-1763https://doi.org/10.1093/eurheartj/ehq142
- The emerging role of carbohydrate antigen 125 in heart failure.Biomark Med. 2020; 14: 249-252https://doi.org/10.2217/bmm-2019-0470
- Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure.Eur Heart J Acute Cardiovasc Care. 2017; 6: 685-696https://doi.org/10.1177/2048872616649757
- Clinical utility of antigen carbohydrate 125 in heart failure.Heart Fail Rev. 2014; 19: 575-584https://doi.org/10.1007/s10741-013-9402-y
- Carbohydrate antigen 125 in heart failure. A new era in the monitoring and control of treatment.Med Clin. 2019; 152: 266-273https://doi.org/10.1016/j.medcli.2018.08.020
- Carbohydrate antigen-125 in heart failure.JACC Heart Fail. 2018; 6: 441-442https://doi.org/10.1016/j.jchf.2018.01.006
- CA125-guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction.Am J Med. 2020; 133: 370-380.e4https://doi.org/10.1016/j.amjmed.2019.07.041
- Carbohydrate antigen-125–guided therapy in acute heart failure.JACC Heart Fail. 2016; 4: 833-843https://doi.org/10.1016/j.jchf.2016.06.007
- Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment.Nat Rev Cardiol. 2020; 17: 641-655https://doi.org/10.1038/s41569-020-0379-7
- Early unplanned readmissions after admission to hospital with heart failure.Am J Cardiol. 2019; 124: 736-745https://doi.org/10.1016/j.amjcard.2020.12.008
- The dilemma, causes and approaches to avoid recurrent hospital readmissions for patients with chronic heart failure.Heart Fail Rev. 2012; 17: 345-353https://doi.org/10.1007/s10741-011-9256-0
- Acute decompensated heart failure (ADHF): a comprehensive contemporary review on preventing early readmissions and postdischarge death.Int J Cardiol. 2016; 223: 1035-1044https://doi.org/10.1016/j.ijcard.2016.07.259
- Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF.Circ Heart Fail. 2013; 6: 727-732https://doi.org/10.1161/CIRCHEARTFAILURE.112.000265
- Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006.JAMA. 2010; 303: 2141-2147https://doi.org/10.1001/jama.2010.748
- The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.Eur J Heart Fail. 2019; 21: 137-155https://doi.org/10.1002/ejhf.1369
- Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine.Eur J Heart Fail. 2010; 12: 423-433https://doi.org/10.1093/eurjhf/hfq045
- A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.Heart Fail Rev. 2012; 17: 485-509https://doi.org/10.1007/s10741-011-9280-0
- NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (Can NT-ProBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?).Circulation. 2018; 137: 1671-1683https://doi.org/10.1161/CIRCULATIONAHA.117.029882
- Rehospitalization for heart failure.J Am Coll Cardiol. 2013; 61: 391-403https://doi.org/10.1016/j.jacc.2012.09.038
- The degree of the predischarge pulmonary congestion in patients hospitalized for worsening heart failure predicts readmission and mortality.Cardiology. 2021; 146: 49-59https://doi.org/10.1159/000510073
- prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure.Int J Cardiol. 2018; 258: 185-191https://doi.org/10.1016/j.ijcard.2018.01.067